Medical Disorders
Resources
Basic InformationLookupsLatest News
When Is It Time for a Knee Replacement?AHA News: Death Rates From Tears In This Major Heart Artery Are Rising, Especially Among Women, Black AdultsOmicron COVID Causing Severe Croup in Young Children'Zapping' Air Passages May Bring Relief for Severe AsthmaModerna Asks FDA to Approve Second Booster for All AdultsNew Tick-Borne Virus Is Spreading Across U.S.Memory Issues Plague Long COVID PatientsCOVID Vaccine Won't Cause Rare Neuro Events, But COVID Infection CouldIt Can Take Weeks for Some Patients With Severe COVID to Recover ConsciousnessOmicron Wave Had 5 Times as Many Small Kids Hospitalized Compared to DeltaPalliative Care Crucial After Severe Stroke, But Many Patients Miss OutMammograms Can Also Highlight Heart Risks: StudyPfizer Asks FDA to Approve Second Booster for SeniorsEven a Little Light in Your Bedroom Could Harm HealthRise in U.K. COVID Cases Closely Watched by U.S. Health OfficialsLong COVID May Bring Long-Term Lung DamageNew Malaria Treatment Gets First Approval for Use in ChildrenAbout 1 in 6 U.S. Couples Disagrees on COVID VaccinationCOVID Meds Appear to Work Against BA.2 Omicron VariantCould Depression Make Dry Eye Worse?When Will Americans With Diabetes Get Relief From High Insulin Prices?COVID's Global Death Toll May Be 3 Times Official NumbersDrug Could Be Non-Antibiotic Alternative to Treat UTIsFlu Vaccine No Match for Circulating Variants This SeasonLymphedema in Legs Strikes 1 in 3 Female Cancer SurvivorsScience Brings Shortcut to Spotting 50 Rare Genetic DiseasesU.S. Airplane, Train and Transit Mask Mandates Extended to April 18Man Who Received First Pig Heart Transplant Has DiedPfizer Begins Trial of COVID Drug Paxlovid in Kids 6 to 17Could a Stool Test Help Spot Pancreatic Cancer?Upcoming Surgery Worry You? Poll Says You're Not AloneHalf of Americans Live With Legacy of Childhood Lead PoisoningIn Reversal, WHO Now Supports COVID BoostersLooking to Neanderthals to Explain Today's Lower Back PainWhat's More Accurate, Blood Pressure Readings at Home or Doctor's Office?Begin Now to Protect Your Heart as Clocks 'Spring Forward'Brain Changes May Fuel 'Long COVID' Anxiety, ConfusionHow COVID-19 Can Change the BrainHeart Defects Could Raise Odds for Severe COVID-196 Healthy Steps to Preventing Colon CancerAHA News: These Three Risk Factors May Have the Biggest Impact on Dementia CasesU.S. Surgeon General Investigates COVID-19 MisinformationCould Your Blood Type Make COVID Worse?Implanted 'Drug Factory' Wipes Out Cancers in Mice -- Could It Help People?Immunization Against Common Infection of Babies Could Be NearTelemedicine Helped Many MS Patients During PandemicMore Years Playing Hockey, Higher Odds for CTE Linked to Head InjuryWhite House Unveils New COVID Response StrategyVariants of COVID Virus May 'Hide Out' in Body: StudyInfected People Gain Long-Lasting Immunity Against Coronavirus: Study
Questions and AnswersVideosLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

New Malaria Treatment Gets First Approval for Use in Children


HealthDay News
Updated: Mar 14th 2022

new article illustration

MONDAY, March 14, 2022 (HealthDay News) -- A new drug that can cure a certain type of malaria was approved in Australia Monday for kids and teens.

The approval was announced on Monday by the nonprofit Medicines for Malaria Venture (MMV), which helped develop the drug with GlaxoSmithKline (GSK). It is for a single dose of tafenoquine (Kozenis) for use in combination with the traditional malaria drug chloroquine. This is the first time the drug has been authorized for use in children and will likely lead to more such approvals worldwide.

Tafenoquine can cure a type of malaria caused by Plasmodium vivax, which is most common in South and Southeast Asia, South America and the Horn of Africa. P. vivax causes up to 5 million malaria infections every year. Children aged 2 to 6 are four times more likely than adults to contract it, MMV said.

"We are proud to have worked with GSK to develop this child-friendly treatment and are thrilled by today's announcement. P. vivax malaria is particularly dangerous for young children for whom repeated relapses can lead to cumulative severe anemia and, in some cases, be fatal. Today, we have a tool to put a stop to the relentless relapse both for adults and children – we are one step closer to defeating this disease," Dr. David Reddy, CEO of MMV, said in a statement.

The drug will be submitted for approval in nine countries, as well as to the World Health Organization, George Jagoe, an executive vice president with MMV, told The New York Times.

In July 2018, the U.S. Food and Drug Administration approved 300 milligrams of tafenoquine for P. vivax malaria in patients 16 and older, and Australia, Brazil, Thailand and Peru followed suit with similar approvals, the Times reported.

The new drug for children is a single 50-milligram tablet dispersed in water, which is much easier to take than the seven- or 14-day course of pills for adults.

About 62% of the children studied experienced some side effects. While none of the side effects were severe, the treatment caused vomiting in about one in five children. At four months, the treatment was 95% effective at preventing recurrence.

Malaria is among the deadliest of infectious diseases and caused 627,000 deaths worldwide in 2020.

Most of these deaths are in sub-Saharan Africa, home to another form of the malaria parasite called Plasmodium falciparum. In October, the World Health Organization backed the first malaria vaccine, also made by GlaxoSmithKline, against P. falciparum.

More information

Visit the U.S. Centers for Disease Control and Prevention for more on malaria.

SOURCES: The New York Times; Medicines for Malaria Venture, statement, March 14, 2022




Facebook

Amazon Smile

 

Children and Adult services are available now with no wait time.  

Please contact HBH at 860-548-0101, option 2.

 


powered by centersite dot net